What's their intention on 797? Did someone have interest, and/or the demise of NGF antibody for them to initiate new phase 2 study in OA pain?
Unless I missed it, I don't think there was a specific mention of why they started up the trials again, which leads me to believe that they started the trials because they now have some additional resources. They referred back to the prior pain benefits 797 showed in the RA and ankylosing spondylitis trials. In the 12-week AS trial, 797 inhibited total back pain compared to placebo throughout the entire 12 weeks and showed evidence of pain relief on top of NSAIDs.
Market Data 
Markets 
AI
